United Kingdom · Series A startup

Who invested in Abselion

One round we have observed, with the 2 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$8.4Mraised across 1 round since 2024, from 1 source

Latest round
Series A, $8.4MDec 2024
Investors
2
See who backed them

The rounds

  1. Dec 2024
    Series A$8.4M

    Also list them on their own siteR42 Group

    Source recorded

Founders and team

From Abselion's own website: 1 founder, 6 on the team.

Ruizhi WangFounder & CEO
  • Jean-Paul DelportHead of Engineering
  • Anne JonesNon-Executive Director
  • Chris MajorBoard Director
  • Dale GordonChairman of the Board
  • Luke RajahBoard Director
  • Oliver HardickBoard Director

Everyone who backed them

Business Growth FundPrivate equity1round
ParkwalkVC firm1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

This firm lists Abselion as a portfolio company on their own website, but no report of a round names it. They are the firms' own claims, kept apart from the rounds above.

R42 GroupVC firm2024, per its site

Quick answers about Abselion

Who invested in Abselion?

Abselion's investors include Business Growth Fund and Parkwalk.

How much has Abselion raised?

Abselion has raised $8.4M across 1 round since 2024.

When did Abselion last raise?

Abselion's most recent round was a Series A of $8.4M in Dec 2024.

What was Abselion's biggest round?

Its most recent round, $8.4M in Dec 2024, is also its largest on record.

Who backed Abselion first?

Abselion's first round on record, in Dec 2024, was backed by Business Growth Fund and Parkwalk.

What stage is Abselion at?

Abselion's latest named round is a Series A, in Dec 2024.

Where is Abselion based?

Abselion is based in the United Kingdom.

Companies like Abselion

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.